# STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)

> **NCT02722369** · PHASE2 · TERMINATED · sponsor: **University College, London** · enrollment: 72 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT02722369
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-14
- **Primary completion:** 2021-03-12
- **Final completion:** 2021-03-12
- **Target enrollment:** 72 (ACTUAL)
- **Why stopped:** Low recruitment, lack of efficacy and increased adverse events in investigational arm.
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722369, "STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02722369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*